Open AccessDevelopment of a Broth Microdilution Method for Exebacase Susceptibility Testing
Author(s) -
Jun Kyun Oh,
Jane E. Ambler,
Cara Cassino,
Raymond Schuch
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02587-20
Subject(s) - broth microdilution , enterococcus faecalis , microbiology and biotechnology , staphylococcus aureus , minimum inhibitory concentration , antimicrobial , medicine , biology , bacteria , genetics
Exebacase (CF-301) belongs to a new class of protein-based antibacterial agents, known as lysins (peptidoglycan hydrolases). Exebacase, a novel lysin with antistaphylococcal activity, is in phase 3 of clinical development.